Lachen

LACHEN, Switzerland, November 15, 2011 - - An Estimated 60,000 Patient Treatments WithoutThromboembolic Events Octapharma today reported that global sales totaled 1.7 million grams of octagam 5% and octagam 10%, [Immune Globulin Intravenous (Human) Liquid Preparation] in the period January 1 through October 30, 2011, an estimated 60,000 treatments, during which there were no reports of thromboembolic events (TEEs).

LACHEN, Switzerland, February 16 - Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG).

LACHEN, Switzerland, January 13 - Octapharma AG, one of the largest plasma products manufacturers in the world, today announced that it has received orphan exclusivity approval for wilate(R) from the U.S.

LACHEN, Switzerland - - With Photo Through June 2009, Octapharma AG realized a record turnover of 536 M euro, compared to 422 M euro as of year-to-date June 2008, an increase of 27%.

LACHEN, Switzerland and HOBOKEN, New Jersey - - ISTH Symposia Discuss Prevention and Eradication of FVIII Inhibitors and Introduce First Recombinant FVIII Produced From a Human Cell Line Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors.